Migraine is a common chronic and often disabling. By Michael J. Marmura, MD and Stephen Silberstein, MD
|
|
- Robert Small
- 5 years ago
- Views:
Transcription
1 By Michael J. Marmura, MD and Stephen Silberstein, MD Migraine is a common chronic and often disabling neurological disorder characterized by attacks of moderate to severe headache. Migraineurs usually experience nausea and light and sound sensitivity during their attacks, and many have aura. Most patients experience reduced ability to function with attacks and many are bed-bound. Migraines can have multiple triggers such as food, sleep changes, or hormonal factors. 1 Often migraineurs elect to treat their headaches without physician consultation using rest or over-the-counter (OTC) medications. Patients who present for evaluation with migraine have usually tried some OTCs without substantial relief. Providers treating migraine must be familiar with different acute treatments, be comfortable with individualizing treatment, and be able to combine treatment modalities. Acute attack medications include specific medications, such as triptans, ergots and dihydroergotamine (DHE), and non-specific medications used for other pain disorders. In selecting acute migraine medication, patients need a treatment plan tailored to their headache type. Mild or moderate intensity attacks often respond to treatment with non-steroidal anti-inflammatory medications (NSAIDs) or combination medications, while more 1 Practical Neurology February 009
2 severe attacks may respond better to specific medications. If the initial treatments fail, rescue medication is needed. This review discusses acute evidence-based and practical treatments for migraine, and specifically focuses on the treatment of intractable headaches such as status migrainosus. Basic Principles In migraine, there are two basic strategies for treatment of acute headache: step care and stratified care. In the step care model, patients usually progress through a sequence of medications usually starting with a simple analgesic, then perhaps an antiemetic, and then a specific medication if the initial treatments are ineffective. 3 This can mean escalating treatment across or within attacks. Stratified care involves treating attacks based on migraine severity. In this model, patients use non-specific medications for minimally disabling attacks, and specific medications for severe attacks. Compared to step care, stratified care improves treatment outcomes, 4 improves quality of life, 5 and reduces costs. 6 Early treatment of migraine attacks improves outcomes. Patients taking triptans early, when the pain is still mild, often have increased pain-free rates at two hours. 7 When taken early, triptans may prevent the development of central sensitization in migraine, 8 as manifested clinically by cutaneous allodynia, which is pain in response to normally non-painful stimuli. Migraineurs with cutaneous allodynia are less likely to respond to triptans. 9 When selecting acute migraine medication, individualize the treatment according to the headache characteristics. For rapidly escalating and disabling attacks, consider injectable medications. Patients with significant nausea or vomiting should use non-oral medications and antiemetics. Migraineurs with attacks that do not respond to specific medication (often with frequent urgent physician or emergency room visits) need a rescue treatment. Before deciding a treatment is ineffective, patients should treat at least two attacks. Other strategies include changing the dose, giving a different formulation or route of administration, or adding a second agent. For patients with frequent headaches, it is important to avoid overuse of acute medication. Medication overuse impacts more migraineurs than patients with other chronic pain disorders 10 and is one cause of chronic daily headache (CDH). Medication overuse headache (MOH) is defined as the use of simple analgesics more than 15 days per month or using triptans, ergots, opioids Compared to step care, stratified care improves treatment outcomes, improves quality of life, and reduces costs. or combination medications more than 10 days a month for more than three months. 11 Frequent opioid and barbiturate use are risk factors for the development of CDH, 1 and stopping these medications can result in increased headache and withdrawal symptoms. MOH requires overuse for at least three months and a history of headaches worsening with the overuse. 13 MOH can cause adverse events (AEs) specific to the class of medication such as ergotism, constipation, gastrointestinal and renal disease, or tardive dyskinesias. Treatment of MOH by withdrawing the offending agent usually improves migraine after a period of increased headache lasting weeks to months. Migraineurs should be aware of MOH and keep a headache calendar (diary) of headaches and acute medication use. 14 Frequent migraines or those that do not respond to acute agents are an indication for prophylaxis. Preventative medications are indicated in patients with 1.) attacks more than once a week,.) acute medication use more than two days per week, 3.) impairment of quality of life or disability despite acute medication use, 4.) complicated migraine conditions such as hemiplegic migraine, and 5.) adverse events or contraindications to acute medication. For example, patients with a contraindication to triptans or ergots, such as coronary artery disease, may need migraine prophylaxis, as acute agents might not be effective. 15 Migraine prophylaxis is indicated in about onethird of all migraineurs, but only three to 13 percent of patients take them. 16 Non-specific Medications NSAIDs. NSAIDs are effective in the acute treatment of migraine. They may work by suppressing inflammation and preventing and treating central sensitization by blocking glial production of prostaglandins. They may also treat non-traditional migraine symptoms, such as neck pain and sinus pressure, that are commonly associated with acute migraine attacks. 17 NSAIDs are less likely to cause MOH than other treatments, 1 but frequent use can lead to undesired systemic AEs such as peptic ulcers or renal disease. Multiple NSAIDS demonstrate effectiveness in migraine. (Table 1) They can be combined with triptans or antiemetics for severe attacks. Opioids. Opioids provide therapeutic benefit in migraine but are associated with a high risk of abuse and dependency. Opioids are most useful in patients with infrequent but disabling migraine, especially if there are contraindications to specific treatments, such as cardiovascular disease or pregnancy. Although AEs may include sedation or confusion, patients might use opioids as February 009 Practical Neurology 13
3 Acute Treatment for Migraine Table 1: NSAIDs effective in migraine Medication Naproxyn Indomethacin Indomethacin-prochlorperazine-caffeine Ketoprofen Piroxicam Ketorolac Route SL Dose (mg) Ibuprofen Diclofenac Aspirin Aspirin-acetominophen-caffeine Tolfenamic acid Celecoxib oral, SL sublingual, intramuscular, - intravenous, suppository a rescue medication to avoid the distress of a visit to the emergency room. Codeine with acetaminophen is effective in migraine, and other opioids commonly used as rescue treatments include fentanyl, hydromorphone, hydrocodone, methadone, morphine, oxycodone, propoxyphene, and pentazocine. Meperdine and is commonly used 18 but may cause paradoxical reactions such as seizures. The agonist-antagonist opioid butorphanol may have lower abuse potential and can be given (-3mg) or as a nasal spray (NS) for migraine. 19 Treatment of frequent migraine with opioids is problematic. Do not use opioids in patients with addictive tendancies, a history of substance abuse, severe psychiatric disorders, or MOH. Patients taking long-term daily opiates for CDH usually do not improve, and many are non-compliant. 0 When using opioids, prescribe with strict limits and monitor the patient closely. Patients should not receive opioid prescriptions from multiple providers. Other analgesics. Acetominophen is effective for migraine at a dose of 1000mg 1 and is useful for patients with contraindications to NSAIDs. Caffeine enhances the effect of other migraine medications and has analgesic properties of its own. Acetominophen and caffeine are often used in combination medications. The combination of isometheptene (a sympathomimetic), dichoralphenazone (a choral hydrate derivative) and acetaminophen is modestly effective for migraine and relatively well tolerated. 3 Contraindications include glaucoma, renal failure, severe hypertension, heart or renal disease and MAO inhibitors. Butalbital-containing analgesics include combinations with acetaminophen or aspirin with caffeine and with or without codeine. No clinical trial demonstrates that butalbital, a barbiturate, adds to the effectiveness of the constituent components, and the risk of dependency and MOH is high. 4 As with opioids, use of butalbital-containing medication must be monitored closely and limited to situations when other treatments are ineffective or contraindicated. Specific Medications Triptans. The development and use of triptans, a class of medications specifically designed to treat acute migraine attacks, has revolutionized migraine treatment. Triptans are selective serotonin receptor agonists, and all have high affinity for 5- HT1B and 5-HT1D receptors, with variable activity at the 5- HT1F receptor. 5 Although initial research suggested triptan effectiveness occurred because of their vasconstrictive properties, their ability to block the transmission of pain signals from the trigeminal nerve to the TNC and prevent release of inflammatory neuropeptides is more important. 6 Triptans are well tolerated and effective, with an excellent safety profile and without the risk of dependence or addiction seen with barbiturate or opioid medications. Currently seven different triptans are available for the treatment of migraine. Each triptan has different pharmacologic properties; some are available in different formulations, such as orally disintegrating tablets, nasal sprays (NS), or subcutaneous injection (SC). 7 (Table ) Deciding which triptan to utilize is patient-dependant: how they metabolize the medication, headache patterns, and what adverse events they can experience. SC sumatriptan is the most effective and fastest-acting triptan but causes the most AEs. 8 A recent meta-analysis of 53 trials evaluating oral triptans compared all oral triptans to sumatriptan 100mg. Rizatriptan 10mg had better efficacy and consistency. Eletriptan 80mg had better efficacy but more AEs. Almotriptan 1.5mg had better pain-free response and fewer AEs. Naratriptan.5mg, frovatriptan.5mg, and sumatriptan 5mg had lower response rates at two hours, but naratriptan.5mg and sumatriptan 5mg were better tolerated than sumatriptan 100mg. Zolmitriptan.5 and 5mg, rizatriptan 5mg and eletriptan 40mg had similar results compared with sumatriptan 100mg. 9 In clinical practice, patients vary in their characteristics and response patterns. Trial and error is often necessary to find the best treatment. 30 If one triptan fails, it is worth trying another. Sumatriptan now is available in a fixed combination with naproxyn. The combination, more effective for migraine than either sumatriptan or naproxyn alone, 31 prevents headache recurrence Practical Neurology February 009
4 Table : Seratonin 5-HT 1b/1d agonists (triptans) Medication Formuations Doses (mg) Tmax (hours) Half-life (hours) Almotriptan Eletriptan Frovatriptan Naratriptan Rizatriptan Sumatriptan Sumatriptan/naproxyn Zolmitriptan (tablet or dissolvable) NS SC (tablet or dissolvable) NS oral, SL sublingual, intramuscular, - intravenous, suppository DHE and Ergotamine. Ergotamine and dihydroergotamine (DHE) are older treatments for moderate-severe migraine that are serotonin agonists with vasoconstrictive and α-adrenergic activity. Ergotamine has more arterial vasoconstriction than DHE, which is a more potent α-adrenergic antagonist with less emetic effect. Ergotamine causes more AEs, especially nausea and vomiting, compared to triptans, which limits its usefulness. 33 Ergotamine is available as suppositories or tablets with and without caffeine. DHE is available as NS, SC or injection, and. Nausea is less common with the NS, SC or forms of DHE than with treatment. 34 To avoid the nausea with DHE treat together with an anti-emetic. DHE is particularly useful for patients with frequent severe migraine and may be less likely to produce MOH than ergots or triptans. Triptans, ergotamine and DHE are contraindicated in patients with ischemic heart disease, vasospasm, uncontrolled hypertension or transient ischemic attacks. 35 In triptan trials, 6.5, 1.5 0, ,.5 5, 10 5, 50, , 6 85/500.5, 5 5 Looking Forward: Needle-free Injections however, the rate of cardiovascular events was very low and most chest pain related to triptan use is not serious or related to ischemia. 36,37 Neuroleptics. Neuroleptics and antiemetics used in migraine are antidopinergic medications that block dopamine at D receptors in the brain. They are usually effective both for improving the nausea or vomiting associated with migraine and treating pain. Neuroleptics are often effective even in severe migraine and many are available as, or treatments. They are effective as rescue medication, and studies suggest neuroleptics are underutilized in the emergency room for the treatment of acute migraine. 38,39 Multiple antidopaminergic medications are useful in migraine. (Table 3) Oral metoclopramide is effective as an adjuvant medication with NSAIDs or triptans and decreases gastric stasis and enhances absorption of other medications. 40 Chlorpromazine, droperidol, prochlorperazine, and haloperidol are all useful in acute migraine, even in refractory cases such as CDH Sedation and extrapyramidal AEs are common. Promethazine and hydroxyzine are treatments for nausea that are less likely to cause extrapyramidal AEs. Seratonin receptor (5- HT3) antagonists may also help treat nausea but do not appear effective for the treatment of migraine pain. 44 A new drug-device combination under consideration by the FDA would deliver sumatriptan subcutaneously without a needle. Sumatriptan Dose-Pro (Zogenix) is described by the developer as a pre-filled, single-use disposable, needle-free drug delivery system designed to deliver 6mg of sumatriptan in 0.5mL of sterile liquid. Patients simply snap off the cap, press the device to a fold of abdominal skin, and depress the plunger. According to data presented at the 50th Annual American Headache Society Meeting in Boston last year and reported by Zogenix, DosePro was bioequivalent to the needle-based autoinjector; healthy volunteers achieved maximum plasma concentrations of sumatriptan within approximately 1 minutes. A second study involving migraine patients demonstrated that 98 percent of patients correctly used the three-step DosePro technology on the first try ~ ~ PN Staff February 009 Practical Neurology 15
5 Acute Treatment for Migraine Table 3: Neuroleptics in migraine Medication Metoclopramide Prochlorperazine Droperidol Chlorpromazine Haloperidol Route oral, SL sublingual, intramuscular, - intravenous, suppository Dose (mg) Special Situations Prodrome and Aura. Treatment of migraine during the prodrome of premonitory symptoms, such as hunger, neck pain, thirst or drowsiness before headache begins, is occasionally effective. Dromperidone 0-40mg and metoclopramide may help prevent attacks, 45 and triptans 46 may be useful, especially in the setting of menstrual migraine. 47 No medication is proven to reverse the neuronal dysfunction of prolonged migraine aura, but case reports suggest magnesium 1000mg, 48 ketamine NS 5mg, 49 carbon dioxide, and cranial transmagnetic stimulation may be effective in some patients. Status migrainosus. Status migrainosus (SM) is defined as a severe migraine attack lasting more than 7 hours. 11 Patients are often debilitated and have used acute medication without relief. Occasionally they will present to emergency departments (EDs) for evaluation and treatment. Treatment outcomes and practices in EDs suggest the current treatment of migraine is often poor. Patients are much more likely to receive opioids than migraine-specific medication such as DHE, and most still have headache and impaired function 4 hours after treatment. 50 Most patients presenting to EDs with headache meet established criteria for migraine, but only a minority receive a migraine diagnosis. 37 The first goal of treatment in the ED is to establish the diagnosis. Common red flags that indicate a secondary headache include new-onset headache, headache with sudden onset ( thunderclap headache ), systemic illness such as fever or immunosupression, older age of onset (over 50 in a patient without a history of headache) or neurological deficits. Patients with SM often require intense treatment, including parenteral therapy. Truly refractory patients with severe disability, medical problems, or MOH should be admitted into the hospital. Principles in the treatment of status migrainosus include: 1. Exclude secondary causes of headache.. Treat intravenously if needed. 3. If medication overuse exists, stop the offending agent. 4. Monitor and treat drug withdrawal. 5. fluids and electrolyte replacement as needed. 6. Treat concurrent nausea and vomiting. 7. Place the patient in a quiet environment with little ambient lighting. 8. Frequent ECGs to monitor QTc (depending on medication) 9. Start migraine prophylaxis. Treatment of SM in the hospital usually begins with fluids and anti-emetics (Table 3) with or without diphenhydramine. This is usually followed by DHE, maximum 3mg per day in three divided doses for up to one week, if there are no contraindications. 43 Adjunctive treatments helpful in some patients include magnesium, sodium valproate 15-0mg/kg rapidly infused, 51 and steroids such as dexamethasone or hydrocortisone. 5 Future Directions Although many treatment options are available in migraine, some patients will still experience profound disability due to their migraine despite treatment. Advances in our understanding of migraine pathophysiology will lead to new treatments in the next few years. Calcitonin gene-related peptide (CGRP) is important in migraine, and CGRP antagonists will soon become available. Initial studies suggest they are effective and well-tolerated. 54 Other potential targets may include adenosine receptor agonists, glutamate receptor antagonists, and nitric oxide synthase inhibitors. 55 Carbon dioxide nasal spray appears promising based on early clinical observations, 56 and there may even be a role for non-medication alternatives such as repetitive transcranial magnetic stimulation for acute migraine with aura. PN Stephen Silberstein, MD is professor of Neurology at Thomas Jefferson University in Philadelphia and on staff at the Jefferson Headache Center. Michael Marmura, MD is assistant professor of Neurology at Thomas Jefferson University in Philadelphia and on staff at the Jefferson Headache Center. 16 Practical Neurology February 009
6 1. Silberstein SD, Lipton RB. Overview of diagnosis and treatment of migraine. Neurology Oct;44(10 Suppl 7):S Lantéri-Minet M. The role of general practitioners in migraine management. Cephalalgia. 008 Sep;8 Suppl : Lipton RB, Silberstein SD. The role of headache-related disability in migraine management: implications for headache treatment guidelines. Neurology. 001;56(6 Suppl 1):S Lipton RB, Baggish JS, Stewart WF, Codispoti JR, Fu M. Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, populationbased study. Arch Intern Med. 000 Dec 11-5;160(): Dahlöf C, Bouchard J, Cortelli P, Heywood J, Jansen JP, Pham S, Hirsch J, Adams J, Miller DW. A multinational investigation of the impact of subcutaneous sumatriptan. II: Health-related quality of life. Pharmacoeconomics. 1997;11 Suppl 1: Williams P, Dowson AJ, Rapoport AM, Sawyer J. The cost effectiveness of stratified care in the management of migraine. Pharmacoeconomics. 001;19(8): Scholpp J, Schellenberg R, Moeckesch B, Banik N. Early treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan. Cephalalgia. 004 Nov;4(11): Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol. 000 May;47(5): Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol. 004 Jan;55(1): Ferrari A, Leone S, Tacchi R, Ferri C, Gallesi D, Giuggioli D, Bertolini A. The link between pain patient and analgesic medication is greater in migraine than in rheumatic disease patients. Cephalalgia. 008 Sep. 11. Ramadan NM, Olesen J. Classification of headache disorders. Semin Neurol. 006 Apr;6(): Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 008 Sep;48(8): Saper JR, Dodick D, Gladstone JP. Management of chronic daily headache: challenges in clinical practice. Headache. 005 Apr;45 Suppl 1:S Rapoport AM. Medication overuse headache: awareness, detection and treatment. CNS Drugs. 008;(1): Dodick, D.W., Silberstein, S.D. Migraine prevention. Practical Neurology. Pract Neurol. 007 Nov;7(6): Lipton, R.B., Bigal, M.E., Diamond, M., Freitag, F., Reed, M.L., Stewart, W.F. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 007 Jan 30;68(5): Silberstein SD, Mannix LK, Goldstein J, Couch JR, Byrd SC, Ames MH, McDonald SA, Lener SE. Multimechanistic (sumatriptan-naproxen) early intervention for the acute treatment of migraine. Neurology. 008 Jul 8;71(): Vinson DR. Treatment patterns of isolated benign headache in US emergency departments. Ann Emerg Med. 00 Mar;39(3): Freitag FG, Diamond M. Emergency treatment of headache. Med Clin North Am May;75(3): Saper JR, Lake AE 3rd, Hamel RL, Lutz TE, Branca B, Sims DB, Kroll MM. Daily scheduled opioids for intractable head pain: long-term observations of a treatment program. Neurology. 004 May 5;6(10): Lipton RB, Baggish JS, Stewart WF, Codispoti JR, Fu M. Efficacy and safety of acetaminophen in the treatment of migraine: results of a randomized, double-blind, placebo-controlled, populationbased study. Arch Intern Med. 000 Dec 11-5;160(): Ward N, Whitney C, Avery D, Dunner D. The analgesic effects of caffeine in headache. Pain Feb;44(): Ryan RE. A study of midrin in the symptomatic relief of migraine headache. Headache Apr;14(1): Young WB, Siow HC. Should butalbital-containing analgesics be banned? Yes. Curr Pain Headache Rep. 00 Apr;6(): Humphrey PP. How it started. Cephalalgia. 001;1 Suppl 1: Spierings EL. The (suma)triptan history revisited. Headache. 000 Oct;40(9): Saxena, and Tfelt-Hansen P. Triptans, 5-HT1B/1D receptor agonists in the acute treatment of migraines. In The Headaches. (Olesen J, Goadsby PJ, Ramadan MN et. al. eds) pp Lippincott Williams & Wilkins, Philadelphia. 8. Göbel H, Heinze A, Stolze H, Heinze-Kuhn K, Lindner V. Open-labeled long-term study of the efficacy, safety, and tolerability of subcutaneous sumatriptan in acute migraine treatment. Cephalalgia Sep;19(7):676-83; discussion Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 001 Nov 17;358(994): Rapoport AM, Tepper SJ, Sheftell FD, Kung E, Bigal ME. Which triptan for which patient? Neurol Sci. 006 May;7 Suppl :S Brandes JL, Kudrow D, Stark SR, O'Carroll CP, Adelman JU, O'Donnell FJ, Alexander WJ, Spruill SE, Barrett PS, Lener SE. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 007 Apr 4;97(13): Krymchantowski AV. Naproxen sodium decreases migraine recurrence when administered with sumatriptan. Arq Neuropsiquiatr. 000 Jun;58(B): Berde, B. Pharmacology of ergot alkaloids in clinical use. Medical Journal of Australia (Suppl. 3), pp Tillgren N. Treatment of headache with dihydroergotamine tartrate. Acta Med Scand. 196: Mathew NT, Dexter J, Couch J, Flamenbaum W, Goldstein J, Rapoport A, Sheftell F, Saper J, Silberstein S, Solomon S, et al Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol. 199 Dec;49(1): Visser WH, Jaspers NM, de Vriend RH, Ferrari MD. Chest symptoms after sumatriptan: a twoyear clinical practice review in 735 consecutive migraine patients. Cephalalgia Dec;16(8): Dodick D, Lipton RB, Martin V, Papademetriou V, Rosamond W, MaassenVanDenBrink A, Loutfi H, Welch KM, Goadsby PJ, Hahn S, Hutchinson S, Matchar D, Silberstein S, Smith TR, Purdy RA, Saiers J; Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 004 May;44(5): Cerbo R, Villani V, Bruti G, Di Stani F, Mostardini C. Primary headache in Emergency Department: prevalence, clinical features and therapeutical approach. J Headache Pain. 005 Sep;6(4): Blumenthal HJ, Weisz MA, Kelly KM, Mayer RL, Blonsky J. Treatment of primary headache in the emergency department. Headache. 003 Nov-Dec;43(10): Albibi R, McCallum RW. Metoclopramide: pharmacology and clinical application. Ann Intern Med Jan;98(1): Evans RW, Young WB. Droperidol and other neuroleptics/antiemetics for the management of migraine. Headache. 003 Jul-Aug;43(7): Wang SJ, Silberstein SD, Young WB. Droperidol treatment of status migrainosus and refractory migraine. Headache Jun;37(6): Silberstein SD, Schulman EA, Hopkins MM. Repetitive intravenous DHE in the treatment of refractory headache. Headache May;30(6): Chappell AS, Bay JM, Botzum GD, Cohen ML. Zatosetron, a 5-HT3 receptor antagonist in a multicenter trial for acute migraine. Neuropharmacology Mar-Apr;33(3-4): Spierings EL. Treatment of the Migraine Attack. In Migraine and Other Headaches. (Ferrari MD and Lataste X eds), pp Parthenon, Park Ridge, New Jersey. 46. Luciani R, Carter D, Mannix L, Hemphill M, Diamond M, Cady R. Prevention of migraine during prodrome with naratriptan. Cephalalgia. 000 Mar;0(): Pringsheim T, Davenport WJ, Dodick D. Acute treatment and prevention of menstrually related migraine headache: evidence-based review. Neurology. 008 Apr ;70(17): Bigal ME, Bordini CA, Tepper SJ, Speciali JG. Intravenous magnesium sulphate in the acute treatment of migraine without aura and migraine with aura. A randomized, double-blind, placebocontrolled study. Cephalalgia. 00 Jun;(5): Kaube H, Herzog J, Käufer T, Dichgans M, Diener HC. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology. 000 Jul 1;55(1): Colman I, Rothney A, Wright SC, Zilkalns B, Rowe BH. Use of narcotic analgesics in the emergency department treatment of migraine headache. Neurology. 004 May 5;6(10): Mathew NT, Kailasam J, Meadors L, Chernyschev O, Gentry P. Intravenous valproate sodium (depacon) aborts migraine rapidly: a preliminary report. Headache. 000 Oct;40(9): Friedman BW, Greenwald P, Bania TC, Esses D, Hochberg M, Solorzano C, Corbo J, Chu J, Chew E, Cheung P, Fearon S, Paternoster J, Baccellieri A, Clark S, Bijur PE, Lipton RB, Gallagher EJ. Randomized trial of dexamethasone for acute migraine in the emergency department. Neurology. 007 Nov 7;69(): Edvinsson L, Petersen KA. CGRP-receptor antagonism in migraine treatment. CNS Neurol Disord Drug Targets. 007 Aug;6(4): Goadsby PJ. Emerging therapies for migraine. Nat Clin Pract Neurol. 007 Nov;3(11): Vause C, Bowen E, Spierings E, Durham P. Effect of carbon dioxide on calcitonin gene-related peptide secretion from trigeminal neurons. Headache. 007 Nov-Dec;47(10): February 009 Practical Neurology 17
Adult & Pediatric Patients. Stanford Health Care, Division Pain Medicine
Acute Treatment Strategies in Adult & Pediatric Patients Theresa Mallick Searle, MS, RN BC, ANP BC Disclosures Speakers Bureau: Allergan, Depomed Acute Treatment Strategies in Adult & Pediatric Patients
More informationADVANCES IN MIGRAINE MANAGEMENT
ADVANCES IN MIGRAINE MANAGEMENT Joanna Girard Katzman, M.D.MSPH Assistant Professor, Dept. of Neurology Project ECHO, Chronic Pain Program University of New Mexico Outline Migraine throughout the decades
More informationMEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache
MEASURE #1: MEDICATION PRESCRIBED FOR ACUTE MIGRAINE ATTACK Headache Measure Description Percentage of patients age 12 years and older with a diagnosis of migraine who were prescribed a guideline recommended
More informationA new questionnaire for assessment of adverse events associated with triptans: methods of assessment influence the results. Preliminary results
J Headache Pain (2004) 5:S112 S116 DOI 10.1007/s10194-004-0123-4 Michele Feleppa Fred D. Sheftell Luciana Ciannella Amedeo D Alessio Giancarlo Apice Nino N. Capobianco Donato M.T. Saracino Walter Di Iorio
More informationMigraine Acute treatment
Migraine Acute treatment Elizabeth Loder, MD, MPH Professor of Neurology, Harvard Medical School Chief, Division of Headache, Department of Neurology, Brigham and Women s Hospital, Boston, MA Disclosures
More informationHMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in
HMFP Comprehensive Headache Center Department of Anesthesia, Critical Care and Pain Medicine Beth Israel Deaconess Medical Center Instructor in Anesthesia and Neurology Harvard Medical School Limited time
More informationInpatient Treatment of Status Migraine With Dihydroergotamine in Children and Adolescents
Headache 2008 the Authors Journal compilation 2008 American Headache Society ISSN 0017-8748 doi: 10.1111/j.1526-4610.2008.01293.x Published by Wiley Periodicals, Inc. Brief Communication Inpatient Treatment
More informationDisclosures. Triptans for Kids 5/16/13
5/16/13 Disclosures Triptans for Kids Amy A. Gelfand, MD GelfandA@neuropeds.ucsf.edu Departments of Neurology and Pediatrics UCSF Child Neurology and Headache Center I receive grant funding from: NIH/NINDS
More informationTABLE 1. Current Diagnostic Criteria for Migraine Without Aura 2 A. At least 5 attacks fulfilling criteria B-D B. Headache attacks lasting 4-72 hours
ANSWERS CONCISE TO FREQUENTLY REVIEW ASKED QUESTIONS FOR CLINICIANS ABOUT MIGRAINE Answers to Frequently Asked Questions About Migraine IVAN GARZA, MD, AND JERRY W. SWANSON, MD Migraine is a common primary
More informationThe best defense is a good offense. Optimizing the Acute Treatment of Migraine. Disclosures 11/10/2017
Optimizing the Acute Treatment of Migraine Brian M. Plato, DO, FAHS Norton Neuroscience Institute Louisville, KY Disclosures Speakers Bureau (personal): Allergan, Depomed, Avanir Research Funding (paid
More informationFaculty Disclosures. Learning Objectives. Acute Treatment Strategies
WWW.AMERICANHEADACHESOCIETY.ORG Acute Treatment Strategies Content developed by: Lawrence C. Newman, MD, FAHS Donna Gutterman, PharmD Faculty Disclosures LAWRENCE C. NEWMAN, MD, FAHS Dr. Newman has received
More informationTreatment Of Medication. Overuse Headache
7 November 2012 BASH GPwSI Meeting Lecture title... Treatment Of Medication Dr... Overuse Headache Dr Marcus Lewis Dr... The National Migraine Centre International Headache Society Diagnostic criteria
More informationmedications. This was an openlabel study consisting of patients with migraines who historically failed to respond to oral triptan
J Headache Pain (2007) 8:13 18 DOI 10.1007/s10194-007-0354-7 ORIGINAL Seymour Diamond Fred G. Freitag Alexander Feoktistov George Nissan Sumatriptan 6 mg subcutaneous as an effective migraine treatment
More informationThe use of combination therapies in the acute management of migraine
REVIEW The use of combination therapies in the acute management of migraine Abouch Valenty Krymchantowski Headache Center of Rio, Rio de Janeiro, Brazil; Outpatient Headache Unit of the Instituto de Neurologia
More informationManagement of headache
Management of headache TJ Steiner Imperial College London Based on European principles of management of common headache disorders TJ Steiner, K Paemeleire, R Jensen, D Valade, L Savi, MJA Lainez, H-C Diener,
More informationONZETRA XSAIL (sumatriptan) nasal powder
ONZETRA XSAIL (sumatriptan) nasal powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationZolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred by patients: a Swedish study of preference in clinical practice
J Headache Pain (2004) 5:237 242 DOI 10.1007/s10194-004-0132-3 ORIGINAL Carl G.H. Dahlöf Mattias Linde Erika Kerekes Zolmitriptan nasal spray provides fast relief of migraine symptoms and is preferred
More informationUpdate on Diagnosis and Management of Migraines
Update on Diagnosis and Management of Migraines Joel J. Heidelbaugh, MD, FAAFP, FACG Clinical Professor Departments of Family Medicine and Urology University of Michigan Learning Objectives To distinguish
More informationTreatment of Headache in the ED
Treatment of Headache in the ED Benjamin W. Friedman, MD, MS, FAAEM Associate professor of Emergency Medicine Albert Einstein College of Medicine Montefiore Medical Center Disclosure Topics of Discussion
More informationSUMAVEL DOSEPRO (sumatriptan succinate) solution for injection
SUMAVEL DOSEPRO (sumatriptan succinate) solution for injection Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit
More informationOveruse of barbiturate and opioid containing medications for primary headache disorders Description
Measure Title Overuse of barbiturate and opioid containing medications for primary headache disorders Description Percentage of s age 12 years and older with a diagnosis of primary headache who were prescribed
More informationManagement options for Migraine. Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM
Management options for Migraine Prof. Dr. Khwaja Nazimuddin Head Dept. of Internal Medicine BIRDEM Assessment The Migraine Disability Assessment Score MIDAS Complete loss of work Partial loss of work Off
More informationHow do we treat migraine? New SIGN Guidelines
How do we treat migraine? New SIGN Guidelines Managing your migraine Migraine Trust, Edinburgh 2018 Callum Duncan Consultant Neurologist Aberdeen Royal Infirmary Chair SIGN Guideline 155 Premonitory Mood
More informationISPUB.COM. C Suthisisang, N Poolsup, N Suksomboon INTRODUCTION
ISPUB.COM The Internet Journal of Pain, Symptom Control and Palliative Care Volume 8 Number 2 Efficacy And Safety Of Sumatriptan Plus Naproxen Sodium In The Acute Treatment Of Migraine: Systematic Review
More informationMEASURE #4: Overuse of Barbiturate Containing Medications for Primary Headache Disorders Headache
MEASURE #4: Overuse of Barbiturate Containing Medications for Primary Headache Disorders Headache Measure Description Percentage of patients age 18 years old and older with a diagnosis of primary headache
More informationGoals. Primary Headache Syndromes. One-Year Prevalence of Common Headache Disorders
Goals One-Year Prevalence of Common Headache Disorders Impact of primary headache syndromes Non pharmacologic Rx of migraine individualized to patient triggers Complementary and alternative Rx of migraine
More information...SELECTED ABSTRACTS...
The following abstracts, from medical journals containing literature on migraine management, were selected for their relevance to this Special Report supplement. Two Sumatriptan Studies Two double-blind
More informationTHE WOMAN WHO COULD NOT DECIDE WHICH MEDICATION TO TAKE
Rapoport Ch 05.qxd 10/15/08 1:06 PM Page 25 CHAPTER 5 THE WOMAN WHO COULD NOT DECIDE WHICH MEDICATION TO TAKE ALLAN PURDY, MD, FRCPC FRED SHEFTELL, MD ALAN RAPOPORT, MD STEWART J. TEPPER, MD Case History
More informationClinical Learning Days November 10, 2017
Migraine Clinical Learning Days November 10, 2017 Alyssa Lettich. MD Neurosciences Institute/Neurosciences Clinical Program Medical Director Headache Disclosures: none Learning Objectives: At the conclusion
More informationUPDATE IN MIGRAINE MANAGEMENT
UPDATE IN MIGRAINE MANAGEMENT Eric P. Baron, DO Cleveland Clinic Neurological Institute Center for Neurological Restoration Headache and Chronic Pain Medicine barone2@ccf.org @Neuralgroover Disclosures
More informationAcute Migraine Treatment: What you and your family should know to help you make the best choices with your doctor
Acute Migraine Treatment: What you and your family should know to help you make the best choices with your doctor TAKE CONTROL OF YOUR MIGRAINES! ABOUT THIS PATIENT GUIDE: Migraine attacks are often debilitating
More informationPatients preference for triptans and other medications as a tool for assessing the efficacy of acute treatments for migraine
J Headache Pain (2005) 6:112 120 DOI 10.1007/s10194-005-0164-3 REVIEW Andrew J. Dowson Stewart J. Tepper Carl Dahlöf Patients preference for triptans and other medications as a tool for assessing the efficacy
More informationAcute migr REVIEW 6 PRACTICAL NEUROLOGY
6 PRACTICAL NEUROLOGY REVIEW Pract Neurol: first published as 10.1111/j.1474-7766.2004.03-205.x on 1 February 2004. Downloaded from http://pn.bmj.com/ Acute migr on 15 July 2018 by guest. Protected by
More informationPrednisone vs. placebo in withdrawal therapy following medication overuse headache
doi:10.1111/j.1468-2982.2007.01488.x Prednisone vs. placebo in withdrawal therapy following medication overuse headache L Pageler 1,2, Z Katsarava 2, HC Diener 2 & V Limmroth 1,2 1 Department of Neurology,
More informationACUTE TREATMENT FOR MIGRAINE. Cristina Tassorelli
The European Headache School 2012 ACUTE TREATMENT FOR MIGRAINE Cristina Tassorelli Headache Science Centre, IRCCS Neurological Institute C. Mondino Foundation - Pavia University Centre for Adaptive Disorders
More informationACUTE MIGRAINE: OLD AND NEW DRUGS JOHN ROBROCK MD FORT WILLIAM FAMILY HEALTH TEAM
ACUTE MIGRAINE: OLD AND NEW DRUGS JOHN ROBROCK MD FORT WILLIAM FAMILY HEALTH TEAM Conflict of Interest Declaration: Nothing to Disclose Presenter: John Robrock, MD Title of Presentation: Acute Migraine:
More informationDespite the widespread use of triptans ... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability
... REPORTS... Almotriptan: A Review of Pharmacology, Clinical Efficacy, and Tolerability Randal L. Von Seggern, PharmD, BCPS Abstract Objective: This article summarizes preclinical and clinical data for
More informationRizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial
J Headache Pain (2007) 8:175 179 DOI 10.1007/s10194-007-0386-7 ORIGINAL Usha Kant Misra Jayantee Kalita Rama Kant Yadav Rizatriptan vs. ibuprofen in migraine: a randomised placebo-controlled trial Received:
More informationRISK FACTORS AND PROGNOSIS OF CHRONIC MIGRAINE
RISK FACTORS AND PROGNOSIS OF CHRONIC MIGRAINE Gretchen E. Tietjen, MD University of Toledo Toledo, Ohio Learning objectives At the conclusion of this presentation, participants should be able to: 1. Understand
More informationANTIMIGRAINE MEDICINES
1 07.00.00.00 - ANTIMIGRAINE MEDICINES 1. Summary statement For acute migraine therapy the following new medicine is proposed: Sumatriptan 50 mg. 2. 3. Global Campaign to Reduce the Burden of Headache
More informationMIGRAINE UPDATE. Objectives & Disclosures. Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment.
MIGRAINE UPDATE Karen L. Bremer, MD November 16, 2018 Objectives & Disclosures Learn techniques used to diagnose headaches. Become familiar with medications used for headache treatment. Disclosure: I am
More informationUTILIZATION MANAGEMENT CRITERIA
SUMATRIPTAN (ALSUMA, IMITREX, SUMAVEL DOSEPRO, ZECUITY ) UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAME: Serotonin 5-HT1 receptor agonists Imitrex (sumatriptan), Alsuma (sumatriptan),
More informationSumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 0 Subject: Sumatriptan Page: 1 of 6 Last Review Date: November 30, 2018 Sumatriptan Description Sumatriptan
More informationHeadache A Practical Approach
Headache A Practical Approach Integrated Pain Symposium December 1, 2017 Alyssa Lettich. MD Neurosciences Institute/Neurosciences Clinical Program Medical Director Headache and Pain Development Teams Disclosures:
More informationAbortive Agents. Available Strengths. Formulary Limits. Tablet: 5mg, 10mg ODT: 5mg, 10 mg 25mg, 50mg, 100mg. 5mg/act, 20mg/act
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Migraine Therapy P&T DATE: 9/12/2017 CLASS: Neurological Disorders REVIEW HISTORY 12/16, 9/15, 2/15, 2/10, 5/07 LOB: MCL
More informationIndex. Prim Care Clin Office Pract 31 (2004) Note: Page numbers of article titles are in boldface type.
Prim Care Clin Office Pract 31 (2004) 441 447 Index Note: Page numbers of article titles are in boldface type. A Abscess, brain, headache in, 388 Acetaminophen for migraine, 406 407 headache from, 369
More informationErgotamine/Dihydroergotamine Products
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationMigraine Management. Roger Cady, MD Headache Care Center Springfield, MO
Migraine Management Roger Cady, MD Headache Care Center Springfield, MO Disclosures Objectives The evolution of migraine From benign episodic (benign) headache to potentially a devastating chronic disease
More informationMigraineurs have specific preferences with regard to migraine therapy. In surveys,
Patient Treatment Preferences and the 5-HT 1B/1D Agonists Robert E. Ryan, Jr, MD REVIEW ARTICLE Migraineurs have specific preferences with regard to migraine therapy. In surveys, they consistently cite
More informationMeasure Components Numerator Statement
MEASURE #5: OVERUSE OF OPIOID CONTAINING MEDICATIONS FOR PRIMARY HEADACHE DISORDERS Headache For Quality Improvement Only. Not to be used for Public Reporting or Accountability Measure Description Percentage
More informationMigraine Migraine Age Specific Prevalence in the United States. Headache International Headache Society Classification
28 Primary Care Medicine Principles and Practice 29 October 28 Professor Peter J. Goadsby Peter.Goadsby@headache.ucsf.edu Department of Neurology Headache International Headache Society Classification
More informationEarly treatment of a migraine attack while pain is still mild increases the efficacy of sumatriptan
Blackwell Science, LtdOxford, UKCHACephalalgia1468-2982Blackwell Science, 20042411925933Original ArticleEarly treatment of migraine with sumatriptanj Scholpp et al. Early treatment of a migraine attack
More informationValue of postmarketing surveillance studies in achieving a complete picture of antimigraine agents: using almotriptan as an example
J Headache Pain (2006) 7:27 33 DOI 10.1007/s10194-006-0266-6 ORIGINAL Julio Pascual Hans-Christoph Diener Hélène Massiou Value of postmarketing surveillance studies in achieving a complete picture of antimigraine
More informationReviews/Evaluations. Medication-Overuse Headache
Reviews/Evaluations Medication-Overuse Headache Population-based studies suggest that the prevalence of chronic daily headache is 3-5%(1,2). Drug-induced headaches are the most common cause of chronic
More informationGet ahead of the ACHE: Monoclonal Antibodies in Migraine Prevention
Get ahead of the ACHE: Monoclonal Antibodies in Migraine Prevention Amanda Janisch, PharmD PGY2 Ambulatory Care Pharmacy Resident MCHS SWMN, Mankato, MN 2018 MFMER slide-1 Disclosures No financial interest
More informationDrug Class Review Triptans
Drug Class Review Triptans April 2013 Last Report: Update #4 (June 2009) The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationShort Clinical Guidelines: Headache, Key Points for Diagnosis and Treatment
Clinical Highlights 1. Headache is diagnosed by history and physical examination with limited need for imaging or laboratory tests. 2. Warning signs of possible disorder other than primary headache are:
More informationSumatriptan Tablets, Nasal Spray (Imitrex), Nasal Powder (Onzetra Xsail), sumatriptan and naproxen sodium (Treximet tablets)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 05.70.10 Subject: Sumatriptan Page: 1 of 6 Last Review Date: March 16, 2018 Sumatriptan Description Sumatriptan
More informationÇiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE
Headache in children and adolescents Çiçek Wöber-Bingöl HEADACHE UNIT FOR CHILDREN AND ADOLESCENCE Dept. of Psychiatry of Childhood and Adolescence Medical University of Vienna, Vienna, Austria Impact
More informationTriptans Quantity Limit Program Summary
Triptans Quantity Limit Program Summary FDA APPROVED INDICATIONS AND DOSAGE 1-13,14,23,24 Agents Amerge (naratriptan) 1, 2.5 tablets Axert (almotriptan) 6.25, 12.5 tablets migraine attacks with/without
More informationDrug Therapy Guidelines
Drug Therapy Guidelines Applicable Medical Benefit Effective: 5/1/18 Pharmacy- Formulary 1 x Next Review: 3/19 Pharmacy- Formulary 2 x Date of Origin: 8/29/06 Triptans: almotriptan, Amerge, Axert, Frova,
More informationInpatient Treatment of Refractory Headache
Inpatient Treatment of Refractory Headache MaryAnn Mays, MD Headache Center Center for Neurological Restoration Neurological Institute Cleveland Clinic Disclosures Speakers Bureau for Allergan, Teva, and
More informationCase Presentation. Case Presentation. Case Presentation. Truths about Headaches (2017) Most headaches were muscle-tension headaches
Agenda Case presentation Migraine Morphology Primary and Premonitory Phase Secondary Headache Aura Headache Primer on Pain Medication Overuse Headache Case Presentation RT is a 25 year old woman with daily
More informationMigraine is a primary headache disorder ... REPORTS... Migraine: Diagnosis, Management, and New Treatment Options
... REPORTS... Migraine: Diagnosis, Management, and New Treatment Options R. Michael Gallagher, DO; and F. Michael Cutrer, MD Abstract Objective: The safety and tolerability of medications used to treat
More informationISSN doi: /head VC 2015 American Headache Society Published by Wiley Periodicals, Inc.
ISSN 0017-8748 Headache doi: 10.1111/head.12746 VC 2015 American Headache Society Published by Wiley Periodicals, Inc. Review Article Acute Treatment Therapies for Pediatric Migraine: A Qualitative Systematic
More informationMigraine Management. Dr Helen Brown Director of Neurology and Stroke The Princess Alexandra Hospital
Migraine Management Dr Helen Brown Director of Neurology and Stroke The Princess Alexandra Hospital Referral Criteria for Migraine Migraine Management Migraine Diagnosis Spot on Health Migraine pathway
More informationTreatment of Primary Headache Syndromes
Presenter Disclosure Information 2:45 3:45pm Treatment of Primary Headache Syndromes SPEAKER Gerald W. Smetana, MD The following relationships exist related to this presentation: Gerald W.Smetana, MD,
More informationAcute Migraine Treatment. Morris Levin, MD Professor of Neurology Director, Headache Center UCSF Department of Neurology San Francisco, CA
Acute Migraine Treatment Morris Levin, MD Professor of Neurology Director, Headache Center UCSF Department of Neurology San Francisco, CA Mo Levin Disclosures Consulting Allergan Supernus Amgen Lilly Royalties
More information10/13/17. Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD
Christy M. Jackson, MD Director, Dalessio Headache Center Scripps Clinic, La Jolla Clinical Professor, Neurosciences UCSD } Depomed Consultant 2014 to present } Avanir Consultant 2014 to present } Amgen
More informationMEASURE #3: PREVENTIVE MIGRAINE MEDICATION PRESCRIBED Headache
MEASURE #3: PREVENTIVE MIGRAINE MEDICATION PRESCRIBED Headache Measure Description Percentage of patients age 18 years old and older diagnosed with migraine headache whose migraine frequency is 4 migraine
More informationTreating Headache Recurrence After Emergency Department Discharge: A Randomized Controlled Trial of Naproxen Versus Sumatriptan
PAIN MANAGEMENT/ORIGINAL RESEARCH Treating Headache Recurrence After Emergency Department Discharge: A Randomized Controlled Trial of Naproxen Versus Sumatriptan Benjamin W. Friedman, MD, MS Clemencia
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
CGRP Page 1 of 13 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: CGRP (calcitonin gene-related peptide) Prime Therapeutics will review Prior Authorization requests
More informationAcute management of menstrually related
ACUTE TREATMENT OF MENSTRUALLY RELATED MIGRAINE * Roger K. Cady, MD ABSTRACT Acute treatment of menstrually related migraine (MRM) focuses not only on prescribing a drug to abort an individual attack,
More informationControlling Migraine Pain
Migraine Stats Controlling Migraine Pain Alan Zacharias, M.D. Associated Neurologists, Boulder Community Health 303-622-3365 Women 15% Men 5% Usually starts in 2 nd and 3 rd Decade Major Impact on days
More informationSumatriptan Injection (Imitrex / Alsuma / Sumavel / Zembrace)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.11 Subject: Sumatriptan Injection Page: 1 of 6 Last Review Date: March 16, 2018 Sumatriptan Injection
More informationTopiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders
J Headache Pain (2012) 13:53 59 DOI 10.1007/s10194-011-0395-4 ORIGINAL Topiramate plus nortriptyline in the preventive treatment of migraine: a controlled study for nonresponders Abouch Valenty Krymchantowski
More informationPrevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D.
Prevention and Treatment of Migraines CAITLIN BARNES, PHARM.D. CANDIDATE AMBULATORY CARE JOE CAMMILLERI, PHARM.D. NATOHYA MALLORY, PHARM.D. Objectives Present patient case Review epidemiology/pathophysiology
More informationMIGRAINE A MYSTERY HEADACHE
MIGRAINE A MYSTERY HEADACHE The migraine is a chronic neurological disease that is characterized by moderate to severe episodes of headache that is mostly associated with other central nervous system (CNS)
More informationPDFlib PLOP: PDF Linearization, Optimization, Protection. Page inserted by evaluation version
PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version www.pdflib.com sales@pdflib.com Headache 2008 the Authors Journal compilation 2008 American Headache Society
More informationEvaluating the triptans
The American Journal of Medicine (2005) Vol 118, Suppl 1, 28S 35S Evaluating the triptans Ninan T. Mathew, MD, a Elizabeth W. Loder, MD b a From the Houston Headache Clinic, and Department of Neurology,
More informationClinical case. Clinical case 3/15/2018 OVERVIEW. Refractory headaches and update on novel treatment. Refractory headache.
OVERVIEW Refractory headaches and update on novel treatment Definition of refractory headache Treatment approach Medications Neuromodulation In the pipeline Juliette Preston, MD OHSU Headache Center Refractory
More informationA case of a patient with chronic headache. Focus on Migraine. None related to the presentation Grants to conduct clinical trials from: Speaker bureau:
Chronic Daily Headache Bassel F. Shneker, MD, MBA Associate Professor Vice Chair, OSU Neurology The Ohio State University Wexner Medical Center Financial Disclosures None related to the presentation Grants
More informationOCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA
OMED 17 OCTOBER 7-10 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA s 122 nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP, ACONP and AOAAM:
More informationCGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS)
CGRP, MONOCLONAL ANTIBODIES AND SMALL MOLECULES (-GEPANTS) Hans-Christoph Diener Senior Professor of Clinical Neurosciences University Duisburg-Essen Germany CGRP, Monoclonal Antibodies and Small Molecules
More informationHeadache Board Review: Pharmacology of Drugs, Guidelines and Evidence-Based
Headache Board Review: Pharmacology of Drugs, Guidelines and Evidence-Based Medicine Michael Marmura Thomas Jefferson University Department of Neurology, Jefferson Headache Center June 9, 2015 Michael.Marmura@Jefferson.edu
More informationMedication For Migraine Chart: Table 1: Acute Treatment when the attack begins
Medication For Migraine Chart: Table 1: Acute Treatment when the attack begins Page a Analgesics (painkillers) Non-steroidal antiinflammatory drugs (NSAIDs) Prescription required Brand Name Formulation
More informationMigraine Controversies in Women s Health. Professor Peter J. Goadsby 5 December Department of Neurology
Migraine 2008 Controversies in Women s Health 5 December 2008 Professor Peter J. Goadsby Peter.Goadsby@headache.ucsf.edu Department of Neurology Headache International Headache Society Classification Primary
More informationPharmacological treatment of attacks in juvenile migraine
J Headache Pain (2004) 5:S62 S66 DOI 10.1007/s10194-004-0110-9 Beatrice Gallai Giovanni Mazzotta Paola Sarchielli Pharmacological treatment of attacks in juvenile migraine Received: Accepted in revised
More informationDrug Class Review Triptans
Drug Class Review Triptans Preliminary Update Scan #3 February 2014 Last Report: Update #4 (June 2009) The purpose of reports is to make available information regarding the comparative clinical effectiveness
More informationARxCH. Annual Review of Changes in Healthcare. Calcitonin Gene-Related Peptide Receptors and the Prevention of Migraines. Abstract
Calcitonin Gene-Related Peptide Receptors and the Prevention of Migraines Brian Schuler, PharmD Candidate 2018 1 1 University of Findlay College of Pharmacy Abstract Migraines are the third most prevalent
More informationSIGN on the pharmacological management of migraine
GUIDELINES SIGN on the pharmacological management of migraine STEVE CHAPLIN In February 2018, the Scottish Intercollegiate Guidelines Network (SIGN) published a new guideline on the pharmacological management
More informationMigraine much more than just a headache
Migraine much more than just a headache Session hosted by Teva UK Limited PUU4 11:15 12:15 UK/NHSS/18/0021b Date of Preparation: August 2018 The views expressed in this presentation are those of the speaker
More informationAn Economic Evaluation of Triptan Products for Migraine
Blackwell Science, LtdOxford, UKVHEValue in Health1098-30152005 ISPOR86647655Original ArticleEconomic Evaluation of TriptansPerfetto et al. Volume 8 Number 6 2005 VALUE IN HEALTH An Economic Evaluation
More informationAn Overview of MOH. ALAN M. Rapoport, M.D. Clinical Professor of Neurology The David Geffen School of Medicine at UCLA Los Angeles, California
An Overview of MOH IHS ASIAN HA MASTERS SCHOOL MARCH 24, 2013 ALAN M. Rapoport, M.D. Clinical Professor of Neurology The David Geffen School of Medicine at UCLA Los Angeles, California President-Elect
More informationMigraine is a common recurrent neurological disorder with
Review Article Department Part 1: Diagnosis, General Management, and Role of Dopamine Antagonists and NSAIDs Vongvaivanich K, MD Kiratikorn Vongvaivanich, MD 1 Keywords: treatment for migraine headache,
More information5 HT receptor agonists (triptans) and Pediatric Migraine Critically Appraised Topic (CAT)
5 HT receptor agonists (triptans) and Pediatric Migraine Critically Appraised Topic (CAT) PICOT Question: In children and adolescents does use of 5 HT receptor agonists (triptans) versus no treatment treat
More informationRelieving migraine pain: Sorting through the options
REVIEW LISA K., MD * Headache specialist, Cincinnati, Ohio Relieving migraine pain: Sorting through the options ABSTRACT Although triptans are a major advance in the treatment of migraine, the optimal
More informationFaculty Disclosure. Karen L. Bremer, MD. Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest.
Faculty Disclosure Karen L. Bremer, MD Dr. Bremer has listed no financial interest/arrangement that would be considered a conflict of interest. HEADACHE UPDATE Karen L. Bremer, MD November 10, 2017 karen.bremer@creighton.edu
More informationPharmacological treatments for acute migraine: quantitative systematic review
Pain 97 (2002) 247 257 www.elsevier.com/locate/pain Pharmacological treatments for acute migraine: quantitative systematic review Anna D. Oldman, Lesley A. Smith, Henry J. McQuay, R. Andrew Moore* Pain
More informationWhat is new in the migraine world! Modar Khalil Consultant neurologist Hull Royal Infirmary
What is new in the migraine world! Modar Khalil Consultant neurologist Hull Royal Infirmary Overview Understanding the burden Commonly used terms Acute therapy What we currently have What we are going
More information